Literature DB >> 20447391

Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities.

Gursev S Dhaunsi1, Mariam H M Yousif, Saghir Akhtar, Mark C Chappell, Debra I Diz, Ibrahim F Benter.   

Abstract

The mechanisms by which angiotensin-(1-7) [Ang-(1-7)] exerts its beneficial effects on end-organ damage associated with diabetes and hypertension are not well understood. The purpose of this study was A) to compare the effects of apocynin with Ang-(1-7) on renal vascular dysfunction and NADPH oxidase activity in a combined model of diabetes and hypertension and B) to further determine whether chronic treatment with Ang-(1-7) can modulate renal catalase, and peroxisome proliferator activated receptor- gamma (PPAR-gamma) levels in streptozotocin-induced diabetes in both normotensive Wistar Kyoto rats (WKY) and in spontaneously hypertensive rats (SHR). Apocynin or Ang-(1-7) treatment for one month starting at the onset of diabetes similarly attenuated elevation of renal NADPH oxidase activity in the diabetic SHR kidney and reduced the degree of proteinuria and hyperglycemia, but had little or modest effect on reducing mean arterial pressure. Both drugs also attenuated the diabetes-induced increase in renal vascular responsiveness to endothelin-1. Induction of diabetes in WKY and SHR animals resulted in significantly reduced renal catalase activity and in PPAR-gamma mRNA and protein levels. Treatment with Ang-(1-7) significantly prevented diabetes-induced reduction in catalase activity and the reduction in PPAR-gamma mRNA and protein levels in both animal models. Taken together, these data suggest that activation of Ang-(1-7)-mediated signaling could be an effective way to prevent the elevation of NADPH oxidase activity and inhibition of PPAR-gamma and catalase activities in diabetes and/or hypertension. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447391      PMCID: PMC2907528          DOI: 10.1016/j.ejphar.2010.04.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  45 in total

Review 1.  Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.

Authors:  Theodore W Kurtz; Michal Pravenec
Journal:  J Hypertens       Date:  2004-12       Impact factor: 4.844

2.  Tissue fractionation studies. 17. Intracellular distribution of monoamine oxidase, aspartate aminotransferase, alanine aminotransferase, D-amino acid oxidase and catalase in rat-liver tissue.

Authors:  P Baudhuin; H Beaufay; Y Rahman-Li; O Z Sellinger; R Wattiaux; P Jacques; C De Duve
Journal:  Biochem J       Date:  1964-07       Impact factor: 3.857

3.  Cardiovascular actions of angiotensin(1-7).

Authors:  I F Benter; D I Diz; C M Ferrario
Journal:  Peptides       Date:  1993 Jul-Aug       Impact factor: 3.750

4.  A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase.

Authors:  G M Small; K Burdett; M J Connock
Journal:  Biochem J       Date:  1985-04-01       Impact factor: 3.857

5.  Effects of NADPH oxidase inhibitor in diabetic nephropathy.

Authors:  Kensuke Asaba; Akihiro Tojo; Maristela Lika Onozato; Atsuo Goto; Mark T Quinn; Toshiro Fujita; Christopher S Wilcox
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

6.  Hereditary catalase deficiencies and increased risk of diabetes.

Authors:  L Góth; J W Eaton
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

Review 7.  PPAR ligands for metabolic disorders.

Authors:  Garret J Etgen; Nathan Mantlo
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

Review 8.  NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology.

Authors:  Randall S Frey; Masuko Ushio-Fukai; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

Review 9.  Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation.

Authors:  Antonio Castrillo; Peter Tontonoz
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

Review 10.  Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.

Authors:  Francesco Locatelli; Bernard Canaud; Kai-Uwe Eckardt; Peter Stenvinkel; Christoph Wanner; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2003-07       Impact factor: 5.992

View more
  25 in total

1.  Unraveling the glomerular RAS: one peptidase at a time.

Authors:  Lisa M Harrison-Bernard; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-09

Review 2.  ACE2: more of Ang-(1-7) or less Ang II?

Authors:  Carlos M Ferrario
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

3.  Molecular and Cellular Effect of Angiotensin 1-7 on Hypertensive Kidney Disease.

Authors:  Yuanjian Chen; Wenyuan Zhao; Chang Liu; Weixin Meng; Tieqiang Zhao; Syamal K Bhattacharya; Yao Sun
Journal:  Am J Hypertens       Date:  2019-04-22       Impact factor: 2.689

Review 4.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

Review 5.  Angiotensin peptides and central autonomic regulation.

Authors:  Debra I Diz; Amy C Arnold; Manisha Nautiyal; Katsunori Isa; Hossam A Shaltout; E Ann Tallant
Journal:  Curr Opin Pharmacol       Date:  2011-02-28       Impact factor: 5.547

6.  Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats.

Authors:  Gábor Raffai; Matthew J Durand; Julian H Lombard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-29       Impact factor: 4.733

7.  Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway.

Authors:  Saghir Akhtar; Mariam H M Yousif; Gursev S Dhaunsi; Bindu Chandrasekhar; Omama Al-Farsi; Ibrahim F Benter
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 8.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

9.  Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?

Authors:  Ranjit Singh Padda; Yixuan Shi; Chao-Sheng Lo; Shao-Ling Zhang; John S D Chan
Journal:  J Diabetes Metab       Date:  2015-10-14

Review 10.  Nonclassical renin-angiotensin system and renal function.

Authors:  Mark C Chappell
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.